Skip to main content
. 2021 May 21;13:421–435. doi: 10.2147/CEOR.S302289

Figure 3.

Figure 3

Time to treatment (in days) and PPPY treatment costs among knee osteoarthritis (OA) patients and controls. *P<0.001 versus control cohort. n/a, limitations inherent to select billing codes resulted in an operational study definition of intra-articular corticosteroid injections of the knee that prevented this treatment modality from being observed within control patients; a diagnosis of knee OA was used to define the injection location, which was a requirement for inclusion in the knee OA cohort.